Skip to content
10-Q

Quarterly Report

Verona Pharma plc

0001657312-24-000025

← back to feed
Filed
Aug 8, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 2, 2024 649.88M sh
Long Term Debt Q2 2024 · Jun 30, 2024 $119.69M
Long Term Debt Q2 2024 · Dec 31, 2023 $48.37M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $404.6M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $271.77M
Current Liabilities Q2 2024 · Jun 30, 2024 $48.35M
Current Liabilities Q2 2024 · Dec 31, 2023 $8.69M
Total Liabilities Q2 2024 · Jun 30, 2024 $265.85M
Total Liabilities Q2 2024 · Dec 31, 2023 $58.84M
Current Assets Q2 2024 · Jun 30, 2024 $416.29M
Current Assets Q2 2024 · Dec 31, 2023 $289.71M
Total Assets Q2 2024 · Jun 30, 2024 $434.12M
Total Assets Q2 2024 · Dec 31, 2023 $308.12M
Shares Diluted restated Q2 2024 · Jun 30, 2023 634.47M sh
Shares Diluted restated Q2 2024 · Jun 30, 2023 628M sh
Capex Q2 2024 · Jun 30, 2023 $0
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$27.09M
Stockholders Equity Q2 2024 · Jun 30, 2023 $273.09M
Stockholders Equity Q2 2024 · Mar 31, 2023 $276.75M
Stockholders Equity Q2 2024 · Dec 31, 2022 $230.47M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.01
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.04
Eps Basic Q2 2024 · Jun 30, 2023 −$0.01
Eps Basic Q2 2024 · Jun 30, 2023 −$0.04
Sga Expense Q2 2024 · Jun 30, 2023 $12.44M
Sga Expense Q2 2024 · Jun 30, 2023 $22.03M
Net Income Q2 2024 · Jun 30, 2023 −$8.81M
Net Income Q2 2024 · Jun 30, 2023 −$25.55M
Net Income Q2 2024 · Mar 31, 2023 −$16.74M
Operating Income Q2 2024 · Jun 30, 2023 −$9.97M
Operating Income Q2 2024 · Jun 30, 2023 −$32.16M